Eli M. Soyfer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eli M. Soyfer has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Angela G. Fleischman
Division of Hematology/Oncology, University of California, Irvine, Irvine, CA
40 shared publications - Jane H. Chen
University of California, Irvine School of Medicine, Irvine, California
38 shared publications - Alexander Himstead
Department of Neurological Surgery, University of California, Irvine
37 shared publications - Amylou Dueck
Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, USA
37 shared publications - Andrew Odegaard
Department of Epidemiology and Biostatistics, Joe C Wen School of Population & Public Health, University of California, Irvine, USA
37 shared publications - Eduard Mas
University of California, Irvine School of Medicine, Irvine, California
37 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Elsevier in SSRN Electronic Journal
Line-of-therapy attrition and durable benefit in stage IV gastroesophageal adenocarcinoma: a global modeling study
BackgroundReferrals to clinical trials of novel agents in stage IV gastroesophageal adenocarcinoma are conventionally placed after standard options are exhausted, although immune checkpoint inhibitors and other monoclonal antibodies now produce durable remissions in this setting. The convention has been questioned by the US Food and Drug Administration initiative Project FrontRunner but has not been quantified for any tumor type.MethodsThis modeling study combined 2022 global incidence estimates, stage-at-diagnosis fractions and real-world line-of-therapy patterns from four health-system contexts to estimate patients reaching each successive line annually. Effect estimates came from every published phase 3 trial reporting a 24-month progression-free survival (PFS) landmark. The outcome was patients per year worldwide progression-free at 24 months who would not otherwise be, calculated as the between-arm difference in 24-month PFS multiplied by patients reaching that line.ResultsAn estimated 1,050,553 new gastroesophageal adenocarcinomas occurred worldwide annually; approximately 693,761 patients had stage IV disease and 504,711 received first-line therapy. The population contracted 9.9-fold between first and third line, to 50,991. Four first-line phase 3 trials spanning two drug classes yielded consistent 24-month PFS differences of 7.0–9.0 percentage points (mean 8.22), corresponding to approximately 41,512 patients per year with durable non-progression versus approximately 9,016 at second line and at most 4,436 at third: 4.6-fold and at least 9.4-fold more, respectively.ConclusionThe benefit forfeited by last-resort trial positioning was large and was attributable almost entirely to patient exposure rather than per-patient drug activity, and was most pronounced where access to later lines is limited.
- 11 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLine-of-therapy attrition and durable benefit in stage IV gastroesophageal adenocarcinoma: a global modeling study
BackgroundReferrals to clinical trials of novel agents in stage IV gastroesophageal adenocarcinoma are conventionally placed after standard options are exhausted, although immune checkpoint inhibitors and other monoclonal antibodies now produce durable remissions in this setting. The convention has been questioned by the US Food and Drug Administration initiative Project FrontRunner but has not been quantified for any tumor type.MethodsThis modeling study combined 2022 global incidence estimates, stage-at-diagnosis fractions and real-world line-of-therapy patterns from four health-system contexts to estimate patients reaching each successive line annually. Effect estimates came from every published phase 3 trial reporting a 24-month progression-free survival (PFS) landmark. The outcome was patients per year worldwide progression-free at 24 months who would not otherwise be, calculated as the between-arm difference in 24-month PFS multiplied by patients reaching that line.ResultsAn estimated 1,050,553 new gastroesophageal adenocarcinomas occurred worldwide annually; approximately 693,761 patients had stage IV disease and 504,711 received first-line therapy. The population contracted 9.9-fold between first and third line, to 50,991. Four first-line phase 3 trials spanning two drug classes yielded consistent 24-month PFS differences of 7.0–9.0 percentage points (mean 8.22), corresponding to approximately 41,512 patients per year with durable non-progression versus approximately 9,016 at second line and at most 4,436 at third: 4.6-fold and at least 9.4-fold more, respectively.ConclusionThe benefit forfeited by last-resort trial positioning was large and was attributable almost entirely to patient exposure rather than per-patient drug activity, and was most pronounced where access to later lines is limited.
- Open Access
Impaired IL-10 Receptor Signaling Leads to Inflammation Induced Exhaustion in Hematopoietic Stem Cells
Hematopoietic stem cells require tight regulation to rapidly initiate emergency hematopoiesis in response to pathogens, but chronic activation leads to proliferation induced exhaustion. Timely reentry into quiescence after inflammatory stimuli is essential for long term sustained HSC maintenance. We identify IL-10R signaling, an established negative feedback regulator in mature myeloid cells, as critical for returning HSCs to quiescence. IL-10R blockade prolongs HSC cycling and sustains activated transcriptional programs after acute inflammation. With chronic exposure, blockade increases cumulative divisions and accelerates aging hallmarks, including myeloid bias, loss of polarity, and functional defects, under conditions that do not otherwise exhaust HSCs when IL-10R signaling is intact. Jak2 V617F mutant HSCs resist the aging acceleration induced by blockade. Consistent with this resistance, IL-10R blocking antibody promotes Jak2 V617F clonal expansion and augments the myeloproliferative neoplasm phenotype. Together, these findings identify IL-10R signaling as a key coordinator of post inflammatory return to quiescence and suggest that modulating this axis could preserve HSCs and shape clonal hematopoiesis. Summary: Wadley et al. show that IL-10 receptor signaling restrains inflammation-induced hematopoietic stem cell cycling and exhaustion; its blockade prolongs cycling, accelerates aging-related decline, and selectively favors Jak2 V617F mutant HSCs, establishing IL-10 signaling as a critical regulator of inflammatory HSC exhaustion and malignant clonal evolution.
Open AccessImpaired IL-10 Receptor Signaling Leads to Inflammation Induced Exhaustion in Hematopoietic Stem Cells
Hematopoietic stem cells require tight regulation to rapidly initiate emergency hematopoiesis in response to pathogens, but chronic activation leads to proliferation induced exhaustion. Timely reentry into quiescence after inflammatory stimuli is essential for long term sustained HSC maintenance. We identify IL-10R signaling, an established negative feedback regulator in mature myeloid cells, as critical for returning HSCs to quiescence. IL-10R blockade prolongs HSC cycling and sustains activated transcriptional programs after acute inflammation. With chronic exposure, blockade increases cumulative divisions and accelerates aging hallmarks, including myeloid bias, loss of polarity, and functional defects, under conditions that do not otherwise exhaust HSCs when IL-10R signaling is intact. Jak2 V617F mutant HSCs resist the aging acceleration induced by blockade. Consistent with this resistance, IL-10R blocking antibody promotes Jak2 V617F clonal expansion and augments the myeloproliferative neoplasm phenotype. Together, these findings identify IL-10R signaling as a key coordinator of post inflammatory return to quiescence and suggest that modulating this axis could preserve HSCs and shape clonal hematopoiesis. Summary: Wadley et al. show that IL-10 receptor signaling restrains inflammation-induced hematopoietic stem cell cycling and exhaustion; its blockade prolongs cycling, accelerates aging-related decline, and selectively favors Jak2 V617F mutant HSCs, establishing IL-10 signaling as a critical regulator of inflammatory HSC exhaustion and malignant clonal evolution.
- Open Access
- 27 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Increased AID results in mutations at the CRLF2 locus implicated in Latin American ALL health disparities
Activation-induced cytidine deaminase (AID) is a B cell-specific mutator required for antibody diversification. However, it is also implicated in the etiology of several B cell malignancies. Evaluating the AID-induced mutation load in patients at-risk for certain blood cancers is critical in assessing disease severity and treatment options. We have developed a digital PCR (dPCR) assay that allows us to quantify mutations resulting from AID modification or DNA double-strand break (DSB) formation and repair at sites known to be prone to DSBs. Implementation of this assay shows that increased AID levels in immature B cells increase genome instability at loci linked to chromosomal translocation formation. This includes the CRLF2 locus that is often involved in translocations associated with a subtype of acute lymphoblastic leukemia (ALL) that disproportionately affects Hispanics, particularly those with Latin American ancestry. Using dPCR, we characterize the CRLF2 locus in B cell-derived genomic DNA from both Hispanic ALL patients and healthy Hispanic donors and found increased mutations in both, suggesting that vulnerability to DNA damage at CRLF2 may be driving this health disparity. Our ability to detect and quantify these mutations will potentiate future risk identification, early detection of cancers, and reduction of associated cancer health disparities.
- 27 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessIncreased AID results in mutations at the CRLF2 locus implicated in Latin American ALL health disparities
Activation-induced cytidine deaminase (AID) is a B cell-specific mutator required for antibody diversification. However, it is also implicated in the etiology of several B cell malignancies. Evaluating the AID-induced mutation load in patients at-risk for certain blood cancers is critical in assessing disease severity and treatment options. We have developed a digital PCR (dPCR) assay that allows us to quantify mutations resulting from AID modification or DNA double-strand break (DSB) formation and repair at sites known to be prone to DSBs. Implementation of this assay shows that increased AID levels in immature B cells increase genome instability at loci linked to chromosomal translocation formation. This includes the CRLF2 locus that is often involved in translocations associated with a subtype of acute lymphoblastic leukemia (ALL) that disproportionately affects Hispanics, particularly those with Latin American ancestry. Using dPCR, we characterize the CRLF2 locus in B cell-derived genomic DNA from both Hispanic ALL patients and healthy Hispanic donors and found increased mutations in both, suggesting that vulnerability to DNA damage at CRLF2 may be driving this health disparity. Our ability to detect and quantify these mutations will potentiate future risk identification, early detection of cancers, and reduction of associated cancer health disparities.
- Open Access
- 12 April 2024
- Published by Elsevier in Blood Neoplasia
- Vol. 1 (2)
Saliva as a feasible alternative to blood for interrogation of somatic hematopoietic variants
- 12 April 2024
- Published by Elsevier in Blood Neoplasia
- Vol. 1 (2)
Open AccessSaliva as a feasible alternative to blood for interrogation of somatic hematopoietic variants
- Open Access
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Changes in symptom burden during study. A, Waterfall plots of percentage change in MPN-SAF (MPN-SAF TSS) at each week compared with baseline (baseline defined as average MPN-SAF TSS of weeks 1 and 2). B, Raw change in specific symptoms at each week compared with baseline (mean ± SD). C, Correlation between change in raw MEDAS score and change in raw MPN-SAF score from baseline to week 9 (left) or baseline to week 12 (right).
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Changes in symptom burden during study. A, Waterfall plots of percentage change in MPN-SAF (MPN-SAF TSS) at each week compared with baseline (baseline defined as average MPN-SAF TSS of weeks 1 and 2). B, Raw change in specific symptoms at each week compared with baseline (mean ± SD). C, Correlation between change in raw MEDAS score and change in raw MPN-SAF score from baseline to week 9 (left) or baseline to week 12 (right).
- Open Access
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
FIGURE 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
FIGURE 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
- Open Access
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
Mediterranean Diet education materials from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Educational materials given to MED diet group
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessMediterranean Diet education materials from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Educational materials given to MED diet group
- Open Access
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Supplementary Table 1. Inclusion and Exclusion Criteria
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Supplementary Table 1. Inclusion and Exclusion Criteria
- Open Access
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
FIGURE 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
FIGURE 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
- Open Access
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Supplementary Figure 3. Changes in JAK2V617F allele burden over time.
- 5 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Supplementary Figure 3. Changes in JAK2V617F allele burden over time.